Pillars of growth
Heavy bet for R&D
as a future
growth engine
Heavy bet on R&D
as a future
growth engine
Biosimilars
A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.
Pharmaceutical products
Diversified portfolio of innovative own and licensed products protected by patents.
Low Molecular Weight Heparin
ROVI's principal product, a low-molecular-weight heparin developed in-house.
Contract manufacturing
High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.
Rovi in figures
+19%
Net profit of the business without R&D in 2018
+42%
2018 LMWHglobal sales
56 countries
Bemiparim international presence with 22 international partners
6 plants
for manufacturing own and third-party products in Spain
€32,4 Mn
of investment in R&D in 2018 Commitment to innovation
7 countries
Direct presence through subsidiaries to market Enoxaparin
Information for investors
Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.
Last news on Rovi
8/05/2019
First quarter 2019 results press release
Download our press release published on 8 May to find out the financial results for the first quarter 2019
Last annual report
Annual Report 2017
Last regular
public information